Addition of aprepitant may improve vomiting control in patients receiving oxaliplatin
the ONA take:
According to results presented at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona, Spain, researchers have found that a three-drug combination antiemetic therapy including aprepitant or fosaprepitant significantly improved the prevention rate of nausea and vomiting in patients receiving oxaliplatin chemotherapy.
For the multicenter, open-label, phase III SENRI Trial, researchers enrolled 413 Japanese patients with colorectal cancer who were receiving oxaliplatin-based chemotherapy. Patients were randomly assigned 1:1 to receive a 5-HT3 receptor antagonist plus dexamethasone with or without aprepitant or fosaprepitant during the first course of chemotherapy. All patients received aprepitant or fosaprepitant in subsequent courses.
Results showed that significantly more patients who received an NK1 antagonist achieved no vomiting overall and no vomiting in the delayed phase than those in the control arm. Researchers also found that women had higher rates of no nausea and complete protection in the aprepitant arm than the control arm.
The standard protocol for prevention of chemotherapy-induced nausea and vomiting in patients receiving oxaliplatin-based chemotherapy is a 5-HT3 receptor antagonist plus dexamethasone.
A three-drug combination antiemetic therapy including aprepitant or fosaprepitant improved the prevention rate of nausea and vomiting.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|